Musallam, Khaled M. http://orcid.org/0000-0003-3935-903X
Barella, Susanna http://orcid.org/0000-0002-1952-7836
Origa, Raffaella http://orcid.org/0000-0002-2346-9616
Ferrero, Giovanni Battista http://orcid.org/0000-0002-3793-5788
Lisi, Roberto
Pasanisi, Annamaria
Longo, Filomena http://orcid.org/0000-0002-0434-0382
Gianesin, Barbara
Forni, Gian Luca http://orcid.org/0000-0001-9833-1016
,
Funding for this research was provided by:
Pharmacosmos A/S
Article History
Received: 8 February 2024
Accepted: 15 March 2024
First Online: 19 March 2024
Declarations
:
: An Ethics Committee approval was obtained at each participating center.
: Written informed consents for data collection and use were retrieved from all patients.
: KMM reports consultancy fees from Novartis, Celgene Corp (Bristol Myers Squibb), Agios Pharmaceuticals, CRISPR Therapeutics, Vifor Pharma, and Pharmacosmos; and research funding from Agios Pharmaceuticals and Pharmacosmos. SB reports being on the advisory board of Vertex Pharmaceuticals and Bristol Myers Squibb and receiving speaker honoraria from Bristol Myers Squibb and Chiesi. RO reports being on the advisory board of Chiesi and Bristol Myers Squibb and consultancy fees from Vertex Pharmaceuticals and Bristol Myers Squibb. GBF reports consultancy fees from Bristol Myers Squibb, Agios Pharmaceuticals, FORMA Therapeutics, Vertex Pharmaceuticals. RL reports receiving speaker honoraria from Bristol Myers Squibb. AP reports receiving speaker honoraria from Bristol Myers Squibb. FL reports being on the advisory board of Vertex Pharmaceuticals and Bristol Myers Squibb. GLF reports receiving speaker honoraria and being on the advisory board Vertex Pharmaceuticals, Bristol Myers Squibb, Hemanext and Garuda Pharmaceuticals. The remaining authors have no relevant financial or non-financial interests to disclose.